Literature DB >> 2450751

Long term inotropic effects of flecainide and propafenone.

E Henze1, J Roth, W Haerer, W E Adam, M Stauch.   

Abstract

This study was undertaken to evaluate the effect of flecainie (Fle) and propafenone (Pro) on rest and exercise myocardial contractility after prolonged oral administration. Standardized, fully automated, gated radionuclide angiograms at rest and during maximum exercise were performed single blinded and prospectively in 19 patients before and after oral treatment with either 150 mg b.i.d. of Fle or 150 mg t.i.d. of Pro. The left ventricular ejection fraction (EF%) as a hemodynamic indicator presented as follows: (Table: see text) In general, there was no significant effect of either drug on resting ventricular function. In only one patient of the Fle group with decreased baseline function did the left ventricular EF fall from 40% to 29%. During exercise, ventricular performance showed deterioration in the Pro group, but, interestingly, improvement in the Fle group. As a result of these opposite changes, the effect of the two drugs on the exercise response of ventricular function was significantly different (P less than 0.05). This study thus gives first evidence that no significant cardiodepressive effects are to be expected after prolonged application of Fle or Pro in normal hearts. There might even be a mild beneficial effect on exercise performance after Fle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450751     DOI: 10.1007/bf02574769

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  16 in total

1.  Propafenone: a new agent for ventricular arrhythmia.

Authors:  P J Podrid; B Lown
Journal:  J Am Coll Cardiol       Date:  1984-07       Impact factor: 24.094

2.  Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.

Authors:  E N Shen; R J Sung; F Morady; A B Schwartz; M M Scheinman; L DiCarlo; W Shapiro
Journal:  J Am Coll Cardiol       Date:  1984-05       Impact factor: 24.094

Review 3.  Haemodynamic effects of encainide, flecainide, lorcainide and tocainide.

Authors:  G Vanhaleweyk; P W Serruys; P G Hugenholtz
Journal:  Eur Heart J       Date:  1984-09       Impact factor: 29.983

4.  Effects of flecainide on ventricular function: clinical and experimental correlations.

Authors:  M A Josephson; N Ikeda; B N Singh
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

5.  The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease.

Authors:  P W Serruys; G Vanhaleweyk; M Van Den Brand; P Verdouw; J Lubsen; P G Hugenholtz
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

6.  [Comparative studies on the cardiodepressant effect of disopyramide, mexiletine and propafenon].

Authors:  C Angermann; H Jahrmärker
Journal:  Z Kardiol       Date:  1983-11

7.  Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

Authors:  M Hodges; J M Haugland; G Granrud; G J Conard; R W Asinger; F L Mikell; J Krejci
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

8.  [The effect of anti-arrhythmic drugs on myocardial function (author's transl)].

Authors:  H A Wester; N Mouselimis
Journal:  Dtsch Med Wochenschr       Date:  1982-08-27       Impact factor: 0.628

9.  Effect of oral propranolol on rest, exercise and postexercise left ventricular performance in normal subjects and patients with coronary artery disease.

Authors:  R C Marshall; G Wisenberg; H R Schelbert; E Henze
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

10.  Flecainide: long-term treatment using a reduced dosing schedule.

Authors:  D Flowers; D O'Gallagher; V Torres; D Miura; J C Somberg
Journal:  Am J Cardiol       Date:  1985-01-01       Impact factor: 2.778

View more
  1 in total

Review 1.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.